{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:38:32Z","timestamp":1787593112804,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":507,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA229092"],"award-info":[{"award-number":["P01 CA229092"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015394","name":"American Society for Transplantation and Cellular Therapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015394","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jtct.2021.10.010","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T10:09:39Z","timestamp":1634638179000},"page":"32.e1-32.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6360-3234","authenticated-orcid":false,"given":"Reid W.","family":"Merryman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Redd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Jeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3521-4012","authenticated-orcid":false,"given":"Jeff L.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Nazzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aine","family":"Varden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Crombie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin I.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7349-0176","authenticated-orcid":false,"given":"Ann S.","family":"LaCasce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Y.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oreofe O.","family":"Odejide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3382-9769","authenticated-orcid":false,"given":"Erin M.","family":"Parry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parastoo B.","family":"Dahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yago","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin M.","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9554-1058","authenticated-orcid":false,"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-7415","authenticated-orcid":false,"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5526-4669","authenticated-orcid":false,"given":"Jerome","family":"Ritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2021.10.010_bib0001","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.10.010_bib0002","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet."},{"key":"10.1016\/j.jtct.2021.10.010_bib0003","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2021.10.010_bib0004","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","article-title":"Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance","volume":"39","author":"Zitvogel","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.jtct.2021.10.010_bib0005","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1172\/JCI98888","article-title":"Bone marrow transplantation generates T cell-dependent control of myeloma in mice","volume":"129","author":"Vuckovic","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2021.10.010_bib0006","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood.V98.3.579","article-title":"Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma","volume":"98","author":"Porrata","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.10.010_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2019.03.009","article-title":"Autograft immune content and survival in non-Hodgkin's lymphoma: a post hoc analysis","volume":"81","author":"Porrata","year":"2019","journal-title":"Leuk Res"},{"key":"10.1016\/j.jtct.2021.10.010_bib0008","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.10.010_bib0009","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.10.010_bib0010","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.10.010_bib0011","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.10.010_bib0012","article-title":"PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation","author":"Armand","year":"2019134","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.10.010_bib0013","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/bloodadvances.2019000784","article-title":"PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation","volume":"4","author":"Frigault","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2021.10.010_bib0014","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.10.010_bib0015","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood-2015-10-672345","article-title":"Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD","volume":"127","author":"Alho","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.10.010_bib0016","article-title":"A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma","volume":"26:1468-1479","author":"Cader","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2021.10.010_bib0017","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2021.10.010_bib0018","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2021.10.010_bib0019","doi-asserted-by":"crossref","first-page":"950","DOI":"10.4049\/jimmunol.1401686","article-title":"Combination therapy with anti\u2013CTLA-4 and anti\u2013PD-1 leads to distinct immunologic changes in vivo","volume":"194","author":"Das","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.jtct.2021.10.010_bib0020","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejca.2020.10.028","article-title":"Dynamic changes in circulating PD-1+ CD8+ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non\u2013small-cell lung cancer","volume":"143","author":"Kim","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtct.2021.10.010_bib0021","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1158\/1078-0432.CCR-18-1449","article-title":"The first-week proliferative response of peripheral blood PD-1+ CD8+ T cells predicts the response to anti-PD-1 therapy in solid tumors","volume":"25","author":"Kim","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2021.10.010_bib0022","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jtct.2021.10.010_bib0023","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081922","article-title":"Anti-PD-1\/PD-l1 based combination immunotherapy to boost antigen-specific CD8+ T cell response in hepatocellular carcinoma","volume":"13","author":"Pe\u00f1a-Asensio","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtct.2021.10.010_bib0024","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.129353","article-title":"Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer","volume":"5","author":"Bar","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jtct.2021.10.010_bib0025","doi-asserted-by":"crossref","first-page":"eaah4573","DOI":"10.1126\/science.aah4573","article-title":"Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors","volume":"356","author":"Villani","year":"2017","journal-title":"Science."},{"key":"10.1016\/j.jtct.2021.10.010_bib0026","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-18570-x","article-title":"PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade","volume":"11","author":"Peng","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtct.2021.10.010_bib0027","doi-asserted-by":"crossref","first-page":"eaav7431","DOI":"10.1126\/scitranslmed.aav7431","article-title":"Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy","volume":"12","author":"Mayoux","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtct.2021.10.010_bib0028","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/bjh.15676","article-title":"Circulating dendritic cells deficiencies as a new biomarker in classical Hodgkin lymphoma","volume":"184","author":"Galati","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.10.010_bib0029","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/JCMA.0000000000000477","article-title":"Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma","volume":"84","author":"Hung","year":"2021","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.jtct.2021.10.010_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102966","article-title":"High PD-L1\/CD274 expression of monocytes and blood dendritic cells is a risk factor in lung cancer patients undergoing treatment with PD1 inhibitor therapy","volume":"12","author":"Riemann","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtct.2021.10.010_bib0031","doi-asserted-by":"crossref","first-page":"111ra120","DOI":"10.1126\/scitranslmed.3003130","article-title":"The PDL1-PD1 axis converts human TH1 cells into regulatory T cells","volume":"3","author":"Amarnath","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtct.2021.10.010_bib0032","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.848.848","article-title":"PD-1 signaling has a critical role in maintaining regulatory T cell homeostasis; implication for Treg depletion therapy by PD-1 blockade","volume":"126","author":"Asano","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.10.010_bib0033","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.10.010_bib0034","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12885-019-6499-y","article-title":"Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells","volume":"20","author":"Yoshida","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtct.2021.10.010_bib0035","unstructured":"Merck Sharp & Dohme. Highlights of prescribing information: Pembrolizumab. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125514lbl.pdf. 2014. Accessed May 2, 2016."},{"key":"10.1016\/j.jtct.2021.10.010_bib0036","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin lymphoma with reduced \u03b22M\/MHC class I expression is associated with inferior outcome independent of 9p24.1 status","volume":"4","author":"Roemer","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtct.2021.10.010_bib0037","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in Classic Hodgkin lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.10.010_bib0038","article-title":"Topological analysis reveals a PD-L1\u2013associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","author":"Carey","year":"2017130","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.10.010_bib0039","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood-2018-04-843714","article-title":"Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment","volume":"132","author":"Cader","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.10.010_bib0040","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-18742-9","article-title":"Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy","volume":"11","author":"Jing","year":"2020","journal-title":"Nat Commun"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721013014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721013014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:00:39Z","timestamp":1763002839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721013014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2666636721013014"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.10.010","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}